- The New Geography of Innovation
- Boston-Cambridge is THE Life Sciences Hub
- Clayton Christensen Demolishes Jill Lepore’s Critique of Disruptive Innovation
- Why isn’t New York City a Biotech Hub?
- Infographic: Top 15 Large Pharma Companies by Market Cap
- Broad Institute Receives $650M for Psychiatric Research
- AbbVie will buy Shire in another Pharma tax inversion strategy
Tag Archives: Boston
From Fierce Biotech, news that the “unending game of global reorganization in biopharma R&D is continuing” with a new move by Takeda to close several vaccine operations around the U.S. in order to concentrate R&D in “the hot Boston/Cambridge, MA hub“
An article in the Wall Street Journal says that high rents are the problem: It also underscores a wider problem for the city as it tries to attract biotech away from thriving centers like San Francisco and Boston—an inability to … Continue reading
In a somewhat surprising development, Boston actually had more venture capital deals than Cambridge in 2013. Ninety-seven deals were signed in Boston, vs. 78 in Cambridge. Cambridge does still hold a commanding lead in the dollar amount, however, with total funding … Continue reading
GEN (Genetic Engineering and Biotechnology News) has released their own, more comprehensive biotech hub rankings. As expected, Boston-Cambridge and the Bay Area are at the top, with San Francisco edging out Boston in most criteria. The GEN rankings include not only … Continue reading
Fierce Biotech has released their latest analysis of venture capital funding of biotech in the U.S. last year, broken down by metropolitan area: Source: http://www.fiercebiotech.com/story/top-15-cities-biotech-venture-funding/2014-03-06 San Francisco is back out in front, edging out Boston-Cambridge. After San Diego and Washington, funding … Continue reading
Most people think of Boston as a global center for research and teaching, especially in the biomedical sciences. (or perhaps as a center of excellence in American professional sports…). Say “financial center”, however, and the word “regional” comes to mind … Continue reading
Luke Timmerman from Xconomy has published an analysis of where the major Life Sciences companies are located. Using the criteria of having $100 million in cash and short term assets as the definition of a major firm, his analysis highlights … Continue reading
… as a cold front pushes tropical air toward the Atlantic ocean.